Biogen (BIIB) Gets a Buy from RBC Capital
In a report released today, Brian Abrahams from RBC Capital maintained a Buy rating on Biogen (BIIB – Research Report), with a price target of ...
BioSpace4h
RFK Jr. Faces the Senate, Sage Rebuffs Biogen, Obesity Space Expands, More
Donald Trump continues to make waves in biopharma; Sage rejects Biogen’s unsolicited takeover offer; the obesity space sees ...
marketinference4h
Sage Therapeutics Rejects Biogen's Acquisition Proposal
While the strategic review process is underway, Sage Therapeutics continues to advance its mission of pioneering solutions to ...
Sage Therapeutics Initiates Strategic Review Process and Rejects Proposal from Biogen
Sage Therapeutics, Inc. filed an 8-K report with the Securities and Exchange Commission. The filing disclosed that the Board of Directors of Sage Therapeutics has commenced a strategic review process ...
Hosted on MSN20h
Sage rejects Biogen’s $469m takeover bid
Sage’s board of directors said that the proposal “significantly undervalues” the company and is not in the best interest of ...
SAGE Rejects Biogen's Offer to Buy Remaining Stake, Stock Up
Sage Therapeutics turns down Biogen's offer to buy the remaining stake in the company and is evaluating strategic alternatives to maximize shareholder value.